Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
NCT07762391
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinary IncontinenceKaramanoğlu Mehmetbey UniversityCompletedNot Applicable
NCT07762391Completed
Not Applicable
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinar...Karamanoğlu Mehmetbey Uni...
NCT07763379
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKAGE FOLLOWING PRIMARY REPAIR IN GASTROINTESTINAL SURGERYSohag UniversityRecruiting
NCT07763379Recruiting
—
THE ROLE OF C-REACTIVE PROTEIN (CRP) IN THE EARLY DIAGNOSIS OF ANASTOMOTIC LEAKA...Sohag University
NCT07763522
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Assessment to Quantify LDH-induced ParesisHelsinki University Central HospitalEnrolling By InvitationNot Applicable
NCT07763522Enrolling By Invitation
Not Applicable
Validation of a Methodology Using Isometric Dynamometer for Ankle STrength Asses...Helsinki University Centr...
NCT07763626
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLDUniversity of GenovaCompletedNot Applicable
NCT07763626Completed
Not Applicable
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLDUniversity of Genova
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07762040
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting Multiple SclerosisAssiut UniversityNot Yet Recruiting
NCT07762040Not Yet Recruiting
—
Predictors of Progression Independent of Relapse Activity in Relapsing Remitting...Assiut University
NCT07764094
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery DiseaseNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764094Recruiting
—
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery...Nanjing First Hospital, N...
NCT07761962
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversible PulpitisKing Abdullah University HospitalActive Not RecruitingNot Applicable
NCT07761962Active Not Recruiting
Not Applicable
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversib...King Abdullah University...
NCT07762664
Photon-Counting CT Versus Conventional CT for Carotid Plaque Assessment in Patients With Carotid Artery StenosisChinese PLA General HospitalRecruiting
NCT07762664Recruiting
—
Photon-Counting CT Versus Conventional CT for Carotid Plaque Assessment in Patie...Chinese PLA General Hospi...
NCT07763483
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de LyonNot Yet Recruiting
NCT07763483Not Yet Recruiting
—
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de Lyon
NCT07763912
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763912Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07763951
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study.ADIUMCompletedNot Applicable
NCT07763951Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762027
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionAssembly BiosciencesNot Yet RecruitingPhase 2
NCT07762027Not Yet Recruiting
Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Part...Assembly Biosciences
NCT07764211
Multimodal Cohort Study of Generalized Anxiety DisorderShanghai Mental Health CenterNot Yet Recruiting
NCT07764211Not Yet Recruiting
—
Multimodal Cohort Study of Generalized Anxiety DisorderShanghai Mental Health Ce...
NCT07763990
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FILLERHallura Ltd.RecruitingNot Applicable
NCT07763990Recruiting
Not Applicable
THE EVALUATION OF THE SAFETY AND PERFORMANCE OF AN INJECTABLE HYALURONIC ACID FI...Hallura Ltd.
NCT07762261
Impact of Generative AI on University Students' Learning Processes and Critical ThinkingAtaturk UniversityNot Yet RecruitingNot Applicable
NCT07762261Not Yet Recruiting
Not Applicable
Impact of Generative AI on University Students' Learning Processes and Critical...Ataturk University
NCT07762755
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen HospitalNot Yet RecruitingPhase 4
NCT07762755Not Yet Recruiting
Phase 4
Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CTBeijing Anzhen Hospital
NCT07762651
Clinical Evaluation of Dentin Replacement Materials in Posterior Composite RestorationsTanta UniversityEnrolling By InvitationNot Applicable
NCT07762651Enrolling By Invitation
Not Applicable
Clinical Evaluation of Dentin Replacement Materials in Posterior Composite Resto...Tanta University
Result Breakdown
Not yet recruiting8 (40%)
Completed5 (25%)
Recruiting4 (20%)
Enrolling by invitation2 (10%)
Active, not recruiting1 (5%)
not_applicable10 (50%)
Not Specified6 (30%)
Phase 12 (10%)
Phase 21 (5%)
Phase 41 (5%)